The 4 analysts offering 1 year price forecasts for BCAX have a max estimate of — and a min estimate of —.
Analyst rating
Based on 5 analysts giving stock ratings to BCAX in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
BCAX EPS for the last quarter is −1.60 USD despite the estimation of −0.41 USD. In the next quarter EPS is expected to reach −0.33 USD. Track more of Bicara Therapeutics Inc. financials and stay on top of what is up with the company.
According to analysts, BCAX price target is 42.05 USD with a max estimate of 48.00 USD and a min estimate of 36.00 USD. Check if this forecast comes true in a year, meanwhile watch Bicara Therapeutics Inc. stock price chart and keep track of the current situation with BCAX news and stock market news.
We've gathered opinions of 5 analysts rating BCAX stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.